Page 12 - Paula Ragan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Paula ragan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Paula Ragan Today - Breaking & Trending Today

Let's Get to Know Paula Ragan, CEO and President of X4 Pharmaceuticals

Let's Get to Know Paula Ragan, CEO and President of X4 Pharmaceuticals
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

Paula Ragan , Henry Termeer , பால ராகன் ,

Pivots During Pandemic Bring Patient-Centric Options to Rare Disease Patients

Published: Mar 01, 2021
By Heather McKenzie
February 28 marked Rare Disease Day, and biotech companies gathered together to raise awareness, advocate for improved access to treatment and let patients know how they are pivoting to improve patient care and access during the COVID-19 pandemic and beyond.
Rezolute Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for patients with metabolic and orphan diseases, was just beginning a Phase IIb study of its lead candidate, RZ358, for Congenital hyperinsulinism (HI), when the chaos struck.
“We have hospitals around the world where the COVID ward was right next to the research ward. We had hospitals that for six months shut down entirely,” shared Erin O’Boyle, Head of Clinical Operations at Rezolute. “We had a lot of overnight stays, but then, right when we were kicking off the study and going into enrollment and starting to activate our sites, COVID hit, and it really kind ....

Michele Rhee , Paula Ragan , Tay Sachs Sandhoff , Erin Oboyle , Gavin Corcoran , Patient Affairs , Rezolute Inc , Rare Disease , Rare Disease Day , Erino Boyle , Clinical Operations , Gene Therapies , Sio Chief Rd Officer , Chief Executive Officer , Vice President , Pivots During Pandemic Bring Patient Centric Options To Rare Disease Patients , மைக்கேல் ரீ , பால ராகன் , கவின் கோர்கோரன் , நோயாளி வாழ்க்கைத்தொழில்கள் , ரேர் நோய் , ரேர் நோய் நாள் , மருத்துவ செயல்பாடுகள் , கீந் சிகிச்சைகள் , சிோ தலைமை ர்ட் அதிகாரி , தலைமை நிர்வாகி அதிகாரி ,

X4 Pharma Adjusts Clinical Trials For a COVID World

X4 Pharma Adjusts Clinical Trials For A COVID World
By Ed Miseta, Chief Editor, Clinical Leader
Follow Me On Twitter @EdClinical
X4 Pharma is a company focused on delivering innovative treatments for patients with rare diseases of the immune system. With the COVID pandemic afflicting patients around the world, those with a compromised immune system were at even greater risk. The company is currently conducting a global Phase 3 trial that was underway when the pandemic hit. The trial is for patients with WHIM Syndrome, who are born immunocompromised. The study is particularly demanding as it is being run in 17 different countries. ....

Paula Ragan , Ed Miseta , Chief Editor , பால ராகன் , தலைமை ஆசிரியர் ,

X4 Pharmaceuticals Appoints Diego Cadavid, M.D., as Chief Medical Officer

Share:
BOSTON, Dec. 14, 2020 (GLOBE NEWSWIRE)
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced the appointment of Diego Cadavid, M.D., as Chief Medical Officer. Dr. Cadavid will be responsible for the strategy, direction and execution of the company s clinical development programs.
We are very pleased to welcome Diego to our team, said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. We believe his strong clinical development expertise, in particular with the advancement of small molecules and biologics for the treatment of rare and immunological diseases, will be invaluable as we continue to advance our ongoing clinical programs, including our Phase 3 trial of mavorixafor in WHIM syndrome and our Phase 1b studies in Waldenström s macroglobulinemia and severe congenital neutropenia, as well as o ....

United States , San Antonio , United Kingdom , University Of Texas , Paula Ragan , Pontificia Universidad Javeriana , Diego Cadavid , Monica Rouco Molina , Armed Forces Institute Of Pathology , Head Of Clinical Development At Fulcrum Therapeutics , University Of Texas Health Science Center , Exchange Commission , Lifesci Communications , Georgetown University , Pharmaceuticals Inc , Chief Medical , Chief Executive Officer , Senior Vice President , Clinical Development , Fulcrum Therapeutics , Senior Medical Director , Massachusetts General Hospital , Texas Health Science Center , Armed Forces Institute , Private Securities Litigation Reform Act , Sci Advisors ,

X4 Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Mavorixafor for the Treatment of WHIM Syndrome

BOSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today ....

United States , Paula Ragan , Rouco Molina , Exchange Commission , Lifesci Communications , European Commission , Drug Administration , Pharmaceuticals Inc , Rare Pediatric Disease , Chief Executive Officer , Fast Track , Fast Track Designation , Breakthrough Therapy Designation , Orphan Drug , Private Securities Litigation Reform Act , ஒன்றுபட்டது மாநிலங்களில் , பால ராகன் , பரிமாற்றம் தரகு , ஐரோப்பிய தரகு , மருந்துகள் இன்க் , ரேர் குழந்தை நோய் , தலைமை நிர்வாகி அதிகாரி , வேகமாக டிராக் , வேகமாக டிராக் பதவி , திருப்புமுனை சிகிச்சை பதவி , ஆர்ஃபந் மருந்து ,